HC Wainwright Maintains Neutral Rating on MacroGenics Shares

HC Wainwright has reaffirmed its neutral rating for shares of MacroGenics, Inc. (NASDAQ: MGNX), as detailed in a research note released on Monday. The brokerage has set a price target of $2.00 for the biopharmaceutical company’s stock. Alongside this rating, HC Wainwright provided estimates for MacroGenics’ earnings, projecting a loss of $0.68 per share for the third quarter of 2025, and a loss of $0.70 per share for the fourth quarter of the same year. For the full fiscal year 2025, earnings are expected to be ($2.61) per share.

In addition, the firm anticipates losses of $0.72, $0.74, $0.76, and $0.78 per share in the first, second, third, and fourth quarters of 2026, respectively. The overall forecast for fiscal year 2026 stands at a loss of $3.01 per share.

Other analysts have also weighed in on MacroGenics recently. On August 15, 2025, Leerink Partners reduced its price target from $8.00 to $5.00 while maintaining an “outperform” rating. Conversely, Wall Street Zen downgraded the company from a “hold” to a “sell” rating on August 2, 2025. Weiss Ratings reaffirmed a “sell (e+)” rating on October 8, 2025. Barclays initiated coverage on September 17, 2025, issuing an “overweight” rating with a target price of $3.00. Overall, one research analyst has given the stock a strong buy rating, one has issued a buy rating, four have assigned a hold rating, and one has issued a sell rating. According to MarketBeat.com, the average rating remains “hold” with a consensus target price of $3.60.

Recent Earnings Performance

MacroGenics reported its most recent quarterly earnings on August 14, 2025. The company posted an earnings per share (EPS) of ($0.57), which exceeded analysts’ expectations of ($0.59) by $0.02. The reported revenue for the quarter was $22.24 million, falling short of the anticipated $28.06 million. The company recorded a negative return on equity of 40.24% and a negative net margin of 21.99%. Analysts forecast an average EPS of ($1.06) for the current year.

Insider Activity and Institutional Investments

In a notable insider transaction, Director William K. Heiden purchased 50,500 shares of MacroGenics on August 19, 2025, at an average price of $1.52 per share, amounting to a total investment of $76,760. Following this acquisition, Heiden’s total ownership increased to 61,500 shares, valued at approximately $93,480. This move represents a significant increase of 459.09% in his holdings. The transaction has been disclosed in a filing with the Securities and Exchange Commission (SEC).

Additionally, institutional investors have been actively adjusting their positions in MacroGenics. For instance, SG Americas Securities LLC increased its stake by 55.9% during the third quarter, now holding 17,179 shares valued at $29,000. Similarly, Cresset Asset Management LLC boosted its holdings by 52.3%, owning 26,720 shares worth $32,000 after acquiring more shares in the second quarter. Other notable institutional movements include State of Wyoming, which raised its position by 41.8%, and XML Financial LLC, which increased its stake by 68.7%.

Currently, institutional investors hold approximately 96.89% of MacroGenics’ stock, reflecting significant confidence in the company’s long-term potential.

MacroGenics specializes in developing, manufacturing, and commercializing antibody-based therapeutics targeting cancer, with its approved product being MARGENZA (margetuximab-cmkb). This treatment is indicated for adults with metastatic HER2-positive breast cancer who have undergone two or more prior anti-HER2 therapies.

As the company navigates a challenging financial landscape, the insights from analysts and insider activities may provide critical guidance for investors considering their positions in MacroGenics.